Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

Core Points - Bavarian Nordic A/S has increased its share capital by DKK 3,818,710 due to the exercise of employee warrants [1] - The capital increase was executed without pre-emption rights for existing shareholders, resulting in total proceeds of DKK 78.7 million [2] - The new shares will be listed on Nasdaq Copenhagen and will have the same rights as existing shares, bringing the total nominal value of share capital to DKK 792,367,280 [3] - The announcement does not alter the company's financial expectations for 2025 [4] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines [5]